MAP kinase activating death domainGenealiases: DEEAH · DENN · IG20 · NEDDISH · RAB3GEP · RabGEF
Q-omics provides the consensus-scored MADD profile across patient tissues and cancer cell-line models. MADD expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MADD is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, MADD RNA expression shows 20,962 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, LIHC, and ACC as cancer lineages where MADD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MADD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MADD survival associations across molecular data types. MADD RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MADD RNA expression–survival associations across cancer types. High MADD expression shows unfavorable associations in KICH, LIHC and COAD, but favorable associations in HNSC, KIRC and LGG. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for MADD RNA expression.
This table summarizes MADD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MADD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MADD shows lower tumor expression in THCA, KICH and KIRP and higher tumor expression in LIHC, CHOL and STAD. The LIHC box plot shows higher MADD RNA expression in tumor versus normal tissue (log2 FC = +1.073, t-test p < 0.001).
This table shows molecular features associated with MADD in patient tissues and cancer cell lines. In patient samples, MADD shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MADD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
